Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients

International Journal of Antimicrobial Agents

Volumn 37, Issue 1, 2011, Pages 46-50

  Cheatham, S Christian ^a   Shea, Katherine M ^b   Healy, Daniel P ^c   Humphrey, Melissa L ^d   Fleming, Megan R ^a   Wack, Matthew F ^e   Smith, David W ^f   Sowinski, Kevin M ^d   Kays, Michael B ^d  

^a St Francis Hospital   (United States)

^b SETON FAMILY OF HOSPITALS   (United States)

^c UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

^d PURDUE UNIVERSITY   (United States)

^e Infectious Diseases of Indiana   (United States)

^f METHODIST HOSPITAL   (United States)

Author keywords

Cefepime; Monte Carlo; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CEFEPIME;

ADULT; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; CITROBACTER; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; ENTEROBACTER; ESCHERICHIA COLI; FEMALE; HOSPITAL PATIENT; HUMAN; KLEBSIELLA PNEUMONIAE; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; OSTEOMYELITIS; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPSIS; SERRATIA MARCESCENS; STEADY STATE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, STATISTICAL; MONTE CARLO METHOD; PLASMA; TIME FACTORS;

EID: 78650276164     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.08.016     Document Type: Conference Paper

References (28)

1. H.S. Sader, T.R. Fritsche, and R.N. Jones Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003) Diagn Microbiol Infect Dis 52 2005 265 273
2. G.G. Zhanel, M. DeCorby, K.A. Nichol, A. Wierzbowski, P.J. Baudry, and J.A. Karlowsky Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006 Diagn Microbiol Infect Dis 62 2008 67 80
3. J.L. Crandon, J.L. Kuti, R.N. Jones, and D.P. Nicolau Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on Gram-negative resistance Ann Pharmacother 43 2009 220 227
4. M.A. Pfaller, H.S. Sader, T.R. Fritsche, and R.N. Jones Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004) Diagn Microbiol Infect Dis 56 2006 63 68
5. Elan Pharmaceutical, Inc. Maxipime (cefepime hydrochloride) package insert. San Francisco, CA: Elan Pharmaceutical, Inc.; 2009
6. W.A. Craig Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1998 1 12
7. T.P. Lodise, B.M. Lomaestro, and G.L. Drusano Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on β-lactam antibiotics Pharmacotherapy 26 2006 1320 1332
8. J.L. Crandon, C.C. Bulik, J.L. Kuti, and D.P. Nicolau Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa Antimicrob Agents Chemother 54 2010 1111 1116
9. J. Lipman, S.C. Wallis, and C. Rickard Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing Antimicrob Agents Chemother 43 1999 2559 2561
10. V.H. Tam, P.S. McKinnon, R.L. Akins, G.L. Drusano, and M.J. Rybak Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function Antimicrob Agents Chemother 47 2003 1853 1861
11. S.V. Bhat, A.Y. Peleg, T.P. Lodise Jr., K.A. Shutt, B. Capitano, and B.A. Potoski Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by Gram-negative organisms Antimicrob Agents Chemother 51 2007 4390 4395
12. American Thoracic Society, and Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Am J Respir Crit Care Med 171 2005 388 416
13. J.F. Roos, J. Bulitta, J. Lipman, and C.M.J. Kirkpatrick Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units J Antimicrob Chemother 58 2006 987 993
14. E.N. Deal, S.T. Micek, R.M. Reichley, and D.J. Ritchie Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter species, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study Clin Ther 31 2009 299 310
15. A.M. Nicasio, R.E. Ariano, S.A. Zelenitsky, A. Kim, J.L. Crandon, and J.L. Kuti Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia Antimicrob Agents Chemother 53 2009 1476 1481
16. C.A. DeRyke, J.L. Kuti, and D.P. Nicolau Pharmacodynamic target attainment of six β-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004 Pharmacotherapy 27 2007 333 342
17. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
18. D.E. Holt, J. de Louvois, R. Hurley, and D. Harvey A high performance liquid chromatography system for the simultaneous assay of some antibiotics commonly found in combination in clinical samples J Antimicrob Chemother 26 1990 107 115
19. C.R. Bonapace, R.L. White, L.V. Friedrich, E.D. Norcross, and J.A. Bosso Pharmacokinetics of cefepime in patients with thermal burn injury Antimicrob Agents Chemother 43 1999 2848 2854
20. P.R. Rhomberg, and R.N. Jones Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005) Diagn Microbiol Infect Dis 57 2007 207 215
21. P.R. Rhomberg, L.M. Deshpande, J.T. Kirby, and R.N. Jones Activity of meropenem as serine carbapenemases evolve in US medical centers: monitoring report from the MYSTIC program (2006) Diagn Microbiol Infect Dis 59 2007 425 432
22. R.N. Jones, J.T. Kirby, and P.R. Rhomberg Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance Diagn Microbiol Infect Dis 61 2008 203 213
23. S.R. Lockhart, M.A. Abramson, S.E. Beekmann, G. Gallagher, S. Riedel, and D.J. Diekema Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004 J Clin Microbiol 45 2007 3352 3359 (Pubitemid 47585661)
24. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Seventeenth informational supplement. Document M100-S17. Wayne, PA: CLSI; 2007
25. A. Kim, C.A. Sutherland, J.L. Kuti, and D.P. Nicolau Optimal dosing of piperacillin/tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Pharmacotherapy 27 2007 1490 1497
26. T.P. Lodise, B. Lomaestro, and G.L. Drusano Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy Clin Infect Dis 44 2007 357 363
27. A.M. Nicasio, K.J. Eagye, D.P. Nicolau, E. Shore, M. Palter, and J. Pepe Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia J Crit Care 25 2010 69 77
28. R.H. Barbhaiya, S.T. Forgue, C.R. Gleason, C.A. Knupp, K.A. Pittman, and D.J. Weidler Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects Antimicrob Agents Chemother 36 1992 552 557